Female Hypoactive Sexual Desire Disorder (HSDD) is defined as a lack of desire for sex that leads to distress and interpersonal difficulties in women. According to the North American Menopause Society, HSDD is the most prevalent sexual disorder in women of all ages. Surgically menopausal women between 20-49 years of age are reported to be more prone to HSDD compared to those who are naturally menopausal.
Flibanserin is a drug that acts on the brain neurotransmitters: dopamine, serotonin, and norepinephrine. The medicine increases the levels of dopamine and norepinephrine while decreasing the levels of serotonin. Owing to concerns about its efficacy, as well as drug safety issues, the FDA rejected the marketing authorization twice for the drug. However, the manufacturer conducted more research and re-submitted the information to the FDA. Based on the collective data, the FDA advisory committee concluded that women using the drug reported a modest increase in satisfactory sexual events when compared to women on placebo and voted 18 to 6 to recommend that the FDA approve Flibanserin for enhancing sexual desire in pre-menopausal women suffering from HSDD.
Accepting the recommendation by the Advisory Committee, the FDA has approved Flibanserin for marketing. Since there are still concerns of serious adverse events, the drug will be marketed with a “Risk Evaluation and Mitigation Strategy” in place for safe use. The drug will also be marketed with a boxed warning.
According to the FDA, the most common adverse reactions associated with the use of Flibanserin are dizziness, somnolence (sleepiness), nausea, fatigue, insomnia and dry mouth. However, the following warnings about Flibanserin have to be taken into consideration as well, to avoid serious adverse events:
Severe low blood pressure and fainting could occur ifSince adverse events are a distinct possibility with the use of Flibanserin, it will only be available through certified medical practitioners and certified pharmacies at this time. Dr. Janet Woodcock, Director of the FDA’s Center for Drug Evaluation and Research, states in the Press Release, “Patients and prescribers should fully understand the risks associated with the use of Addyi (Flibanserin) before considering treatment.”
Dr. Janet Woodcock says, “Today’s approval provides women distressed by their low sexual desire with an approved treatment option. The FDA strives to protect and advance the health of women, and we are committed to supporting the development of safe and effective treatments for female sexual dysfunction.”
If women using Flibanserin experience adverse events, they are requested to contact FDA at:
Telephone-1-800-FDA-1088
Online: www.fda.gov/MedWatch
Primary Reference
U.S. Food and Drug Administration. (n.d.). Retrieved August 19, 2015, from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm458734.htm
DoveMed Resources
Female Hypoactive Sexual Desire Disorder. (n.d.). Retrieved August 19, 2015, from http://www.dovemed.com/diseases-conditions/female-hypoactive-sexual-desire-disorder/
The US Food And Drug Administration's Advisory Committee Recommends Approval Of Flibanserin, A Drug That Improves Libido In Women. (n.d.). Retrieved August 19, 2015, from http://www.dovemed.com/current-medical-news/fda-flibanserin/
Additional Reference
(n.d.). Retrieved August 18, 2015, from http://www.menopause.org/docs/default-document-library/hsddkingsberg.pdf?sfvrsn=2
and connect with fellow professionals
At DoveMed, our utmost priority is your well-being. We are an online medical resource dedicated to providing you with accurate and up-to-date information on a wide range of medical topics. But we're more than just an information hub - we genuinely care about your health journey. That's why we offer a variety of products tailored for both healthcare consumers and professionals, because we believe in empowering everyone involved in the care process.
Our mission is to create a user-friendly healthcare technology portal that helps you make better decisions about your overall health and well-being. We understand that navigating the complexities of healthcare can be overwhelming, so we strive to be a reliable and compassionate companion on your path to wellness.
As an impartial and trusted online resource, we connect healthcare seekers, physicians, and hospitals in a marketplace that promotes a higher quality, easy-to-use healthcare experience. You can trust that our content is unbiased and impartial, as it is trusted by physicians, researchers, and university professors around the globe. Importantly, we are not influenced or owned by any pharmaceutical, medical, or media companies. At DoveMed, we are a group of passionate individuals who deeply care about improving health and wellness for people everywhere. Your well-being is at the heart of everything we do.
0 Comments
Please log in to post a comment.